



1644

PATENT**Attorney Docket No.** 350013-66#24/E
GND
11/8/02**CERTIFICATE OF MAILING**

I hereby certify that on October 29, 2002, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, BOX SEQUENCE, P.O. Box 2327, Arlington, VA 22202

37 CFR 1.8(a)

 with sufficient postage
as first class mail

37 CFR 1.10

 as "Express Mail Post Office
to Addressee" Mailing Label
No.

Florence Thys-Doucet

(Type or print name of person mailing paper)

(Signature of person mailing paper)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent and Trademark Office
BOX SEQUENCE, P.O. Box 2327
Arlington, VA 22202

**SUBMISSION OF SEQUENCE LISTING, COMPUTER READABLE COPY
AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY
INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
(37 CFR §§ 1.821-1.825)**

Dear Ms. DeCloux:

Responsive to the Notice to Comply, mailed October 10, 2002, Applicant enclose herewith a copy of the SEQUENCE LISTING in computer readable (ASCII) form and as an MS Word document. A paper copy of the SEQUENCE LISTING in compliance with 37 CFR §§ 1.821-1.825 for the nucleotide and amino acid sequences disclosed in the above-referenced application is also submitted herewith.

**STATEMENT THAT COMPUTER READABLE COPY OF
THE SUBSTITUTE SEQUENCE LISTING IS THE SAME AS THE
PAPER COPY OF THE SUBSTITUTE SEQUENCE LISTING**

I hereby state:

1. The computer readable (ASCII) form and the MS Word document of the SUBSTITUTE SEQUENCE LISTING submitted in this application is the same as the paper copy of the SUBSTITUTE SEQUENCE LISTING to which it is indicated to relate.

2. All papers accompanying this submission introduce no new matter to the accompanying application.

VERIFICATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

The Commissioner is hereby authorized to charge any additional filing fees under 37 C.F.R. § 1.16, or application processing fees under 37 C.F.R. § 1.17, which may be required now or during the pendency of this application, or credit any overpayment to Account No. 16-2230.

Respectfully submitted,



Guy Porter Smith, Reg. No. 20,142
OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East, Suite 3800
Los Angeles, California 90067
(310) 788-5000

Dated: October 22, 2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:

RECEIVED

OCT 31 2002

Applicant Must Provide:

TECH CENTER 1600/2900

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600


PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

1600

CRF Problem Report



TECHNOLOGY
SYSTEMS
BRANCH



1644

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/424,091B

Filing Date: 2/23/2000

Date Processed by STIC: 7/29/2002

DTH22

TECH CENTER 1600/2900

AUG 06 2002

RECEIVED

OCT 31 2002

TECH CENTER 1600/2900

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

The CRF (was):

- Damaged or Unreadable (for Unreadable, see attached)
 Blank (no files on CRF) (see attached)
 Empty file (filename present, but no bytes in file) (see attached)
 Virus-infected. Virus name: _____ The STIC will not process the CRF.
 Not saved in ASCII text
 Sequence Listing was embedded in the file. According to Sequence Rules,
submitted file should only be the Sequence Listing.
 Did not contain a Sequence Listing. (see attached sample)
 Other:

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>) , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
Federal Express, United Parcel Service , or other delivery service to : U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002